We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Blood Test for Myocardial Infarction Tested

By LabMedica International staff writers
Posted on 19 Jun 2019
The level cardiac myosin-binding protein C (cMyC) in the blood increase more rapidly after a myocardial infarction, and to a higher extent, than troponin. More...
This means meaning that the new test can rule out a myocardial infarction in a higher proportion of patients straight away.

Under current UK guidelines, people suspected of having a myocardial infarction are tested for high blood troponin levels as soon as they arrive in an Accident and Emergency department (A&E), and again after three hours. Depending on the type of troponin test used, up to 85% of people will need to remain in hospital for further tests in order to rule out a heart attack.

An international team of scientists working with King’s College London (London, UK) took blood from 776 patients traveling to hospital by ambulance in Denmark. In patients who did experience myocardial infarction, the protein was present in high enough concentrations 95% of the time for an on-the spot diagnosis. Importantly, the cMyC test outperformed the existing troponin test, which was only capable of diagnosing around 40% of patients in this way.

The cMyC blood test, developed by a team from King’s College London and tested across Europe, has already been shown to rapidly rule out a heart attack in more people than the standard troponin test. The team hopes to work with industry to create a portable testing device to be used in UK A&E departments. The test could also be used in ambulances in countries where ambulances have to drive considerable distances to get patients to their nearest hospital. The press release states that a simple handheld device could replace the time-consuming processes involved in sending samples to the hospital labs for analysis.

Tom Kaier, MD, PhD, a lead author of the study, said, “It is important for both patients and doctors to work out early who has had a heart attack and who has not. Now that we know that this test is sensitive enough to give an almost immediate heart attack diagnosis, we need to work on developing a testing device. We’d love to see this used in A&E departments within the next five years.” The study was presented at the British Cardiovascular Society Conference held June 4-6, 2019, in Manchester, UK.

Related Links:
King’s College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Urinalysis Solution
UN-9000
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.